Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice.

Vollaire J, Machuca-Gayet I, Lavaud J, Bellanger A, Bouazza L, El Moghrabi S, Treilleux I, Coll JL, Peyruchaud O, Josserand V, Cohen PA.

Front Pharmacol. 2019 Jun 19;10:667. doi: 10.3389/fphar.2019.00667. eCollection 2019.

2.

[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting].

Maran-Gonzalez A, Franchet C, Duprez-Paumier R, Antoine M, Barlier C, Becette V, Berghian A, Blanc-Fournier C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Fleury C, Garbar C, Ghnassia JP, Haudebourg J, MacGrogan G, Mathieu MC, Michenet P, Penault-Llorca F, Poulet B, Robin Y, Roger P, Russ E, Treilleux I, Valent A, Verriele V, Vincent-Salomon A, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2019 Jun 27. pii: S0242-6498(19)30089-6. doi: 10.1016/j.annpat.2019.04.004. [Epub ahead of print] French.

PMID:
31257035
3.

Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer.

Poulard C, Jacquemetton J, Trédan O, Cohen PA, Vendrell J, Ghayad SE, Treilleux I, Marangoni E, Le Romancer M.

Int J Mol Sci. 2019 Jun 5;20(11). pii: E2773. doi: 10.3390/ijms20112773.

4.

Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers.

Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Daraï E, Chabbert-Buffet N, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, Thibault MR, Ferron G, Devouassoux M, Kurtz JE, Provansal M, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I.

Eur J Cancer. 2019 Jul;116:35-44. doi: 10.1016/j.ejca.2019.04.018. Epub 2019 Jun 3.

PMID:
31170563
5.

Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis.

Chefdeville A, Treilleux I, Mayeur ME, Couillault C, Picard G, Bost C, Mokhtari K, Vasiljevic A, Meyronet D, Rogemond V, Psimaras D, Dubois B, Honnorat J, Desestret V.

Acta Neuropathol Commun. 2019 Mar 11;7(1):38. doi: 10.1186/s40478-019-0693-7.

6.

The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer.

Choucair A, Pham TH, Omarjee S, Jacquemetton J, Kassem L, Trédan O, Rambaud J, Marangoni E, Corbo L, Treilleux I, Le Romancer M.

Oncogene. 2019 May;38(21):4015-4027. doi: 10.1038/s41388-019-0694-9. Epub 2019 Jan 28.

7.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

PMID:
30659290
8.

LKB1 regulates PRMT5 activity in breast cancer.

Lattouf H, Kassem L, Jacquemetton J, Choucair A, Poulard C, Trédan O, Corbo L, Diab-Assaf M, Hussein N, Treilleux I, Le Romancer M.

Int J Cancer. 2019 Feb 1;144(3):595-606. doi: 10.1002/ijc.31909. Epub 2018 Oct 31.

PMID:
30289978
9.

CD73 expression and clinical significance in human metastatic melanoma.

Monteiro I, Vigano S, Faouzi M, Treilleux I, Michielin O, Ménétrier-Caux C, Caux C, Romero P, de Leval L.

Oncotarget. 2018 Jun 1;9(42):26659-26669. doi: 10.18632/oncotarget.25426. eCollection 2018 Jun 1.

10.

Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer.

Drouet Y, Treilleux I, Viari A, Léon S, Devouassoux-Shisheboran M, Voirin N, de la Fouchardière C, Manship B, Puisieux A, Lasset C, Moyret-Lalle C.

Sci Rep. 2018 May 9;8(1):7386. doi: 10.1038/s41598-018-25631-1.

11.

High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.

Bataillon G, Fuhrmann L, Girard E, Menet E, Laé M, Capovilla M, Treilleux I, Arnould L, Penault-Llorca F, Rouzier R, Marchiò C, Bieche I, Vincent-Salomon A.

Histopathology. 2018 Aug;73(2):273-283. doi: 10.1111/his.13514. Epub 2018 May 7.

12.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Chabbert-Buffet N, Daraï E, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, de la Motte Rouge T, Ferron G, Devouassoux-Shisheboran M, Kurtz JE, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I.

Bull Cancer. 2018 Mar;105(3):299-314. doi: 10.1016/j.bulcan.2017.10.032. French.

PMID:
29397916
13.

Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10.

Nougarede A, Popgeorgiev N, Kassem L, Omarjee S, Borel S, Mikaelian I, Lopez J, Gadet R, Marcillat O, Treilleux I, Villoutreix BO, Rimokh R, Gillet G.

Cancer Res. 2018 Mar 15;78(6):1404-1417. doi: 10.1158/0008-5472.CAN-17-0846. Epub 2018 Jan 12.

14.

Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.

Small M, Treilleux I, Couillault C, Pissaloux D, Picard G, Paindavoine S, Attignon V, Wang Q, Rogemond V, Lay S, Ray-Coquard I, Pfisterer J, Joly F, Du Bois A, Psimaras D, Bendriss-Vermare N, Caux C, Dubois B, Honnorat J, Desestret V.

Acta Neuropathol. 2018 Apr;135(4):569-579. doi: 10.1007/s00401-017-1802-y. Epub 2018 Jan 3.

PMID:
29299667
15.

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.

Dantas-Barbosa C, Lesluyes T, Loarer FL, Chibon F, Treilleux I, Coindre JM, Meeus P, Brahmi M, Bally O, Ray-Coquard I, Sunyach MP, Cesne AL, Mir O, Bonvalot S, Toulmonde M, Italiano A, Saintigny P, Jean-Denis M, Ducimetiere F, Ranchere D, El Sayadi H, Alberti L, Blay JY.

Br J Cancer. 2017 Dec 5;117(12):1787-1797. doi: 10.1038/bjc.2017.354. Epub 2017 Oct 12.

16.

Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRASG12D-driven Pancreatic Tumorigenesis.

Chuvin N, Vincent DF, Pommier RM, Alcaraz LB, Gout J, Caligaris C, Yacoub K, Cardot V, Roger E, Kaniewski B, Martel S, Cintas C, Goddard-Léon S, Colombe A, Valantin J, Gadot N, Servoz E, Morton J, Goddard I, Couvelard A, Rebours V, Guillermet J, Sansom OJ, Treilleux I, Valcourt U, Sentis S, Dubus P, Bartholin L.

Cell Mol Gastroenterol Hepatol. 2017 May 31;4(2):263-282. doi: 10.1016/j.jcmgh.2017.05.005. eCollection 2017 Sep.

17.

Non-canonical NOTCH3 signalling limits tumour angiogenesis.

Lin S, Negulescu A, Bulusu S, Gibert B, Delcros JG, Ducarouge B, Rama N, Gadot N, Treilleux I, Saintigny P, Meurette O, Mehlen P.

Nat Commun. 2017 Jul 18;8:16074. doi: 10.1038/ncomms16074.

18.

Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4.

Royet A, Broutier L, Coissieux MM, Malleval C, Gadot N, Maillet D, Gratadou-Hupon L, Bernet A, Nony P, Treilleux I, Honnorat J, Liebl D, Pelletier L, Berger F, Meyronet D, Castets M, Mehlen P.

Oncotarget. 2017 Apr 4;8(14):23750-23759. doi: 10.18632/oncotarget.16077.

19.

Networking for ovarian rare tumors: a significant breakthrough improving disease management.

Chiannilkulchai N, Pautier P, Genestie C, Bats AS, Vacher-Lavenu MC, Devouassoux-Shisheboran M, Treilleux I, Floquet A, Croce S, Ferron G, Mery E, Pomel C, Penault-Llorca F, Lefeuvre-Plesse C, Henno S, Leblanc E, Lemaire AS, Averous G, Kurtz JE, Ray-Coquard I.

Ann Oncol. 2017 Jun 1;28(6):1274-1279. doi: 10.1093/annonc/mdx099.

PMID:
28398524
20.

The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.

Bellanger A, Donini CF, Vendrell JA, Lavaud J, Machuca-Gayet I, Ruel M, Vollaire J, Grisard E, Győrffy B, Bièche I, Peyruchaud O, Coll JL, Treilleux I, Maguer-Satta V, Josserand V, Cohen PA.

J Pathol. 2017 May;242(1):73-89. doi: 10.1002/path.4882. Epub 2017 Mar 27.

PMID:
28207159
21.

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.

Heudel PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, Roche-Forestier S, Meunier J, Foa C, You B, Priou F, Tazi Y, Floquet A, Selle F, Berton-Rigaud D, Lesoin A, Kalbacher E, Lortholary A, Favier L, Treilleux I, Ray-Coquard I.

Br J Cancer. 2017 Jan;116(3):303-309. doi: 10.1038/bjc.2016.430. Epub 2017 Jan 10.

22.

The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer.

Omarjee S, Jacquemetton J, Poulard C, Rochel N, Dejaegere A, Chebaro Y, Treilleux I, Marangoni E, Corbo L, Romancer ML.

Oncogene. 2017 May 4;36(18):2503-2514. doi: 10.1038/onc.2016.415. Epub 2016 Dec 12.

23.

Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling.

Clément F, Xu X, Donini CF, Clément A, Omarjee S, Delay E, Treilleux I, Fervers B, Le Romancer M, Cohen PA, Maguer-Satta V.

Cell Death Differ. 2017 Jan;24(1):155-166. doi: 10.1038/cdd.2016.107. Epub 2016 Oct 14.

24.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G.

Nat Commun. 2016 Jul 13;7:12222. doi: 10.1038/ncomms12222.

25.

Surgical Management of Benign and Borderline Phyllodes Tumors of the Breast.

Moutte A, Chopin N, Faure C, Beurrier F, Ho Quoc C, Guinaudeau F, Treilleux I, Carrabin N.

Breast J. 2016 Sep;22(5):547-52. doi: 10.1111/tbj.12623. Epub 2016 Jun 6.

PMID:
27265474
26.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2. Erratum in: Nature. 2019 Feb;566(7742):E1.

27.

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.

Azim HA, Kassem L, Treilleux I, Wang Q, El Enein MA, Anis SE, Bachelot T.

Transl Oncol. 2016 Apr;9(2):114-123. doi: 10.1016/j.tranon.2016.01.001.

28.

CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis.

Desestret V, Chefdeville A, Viaccoz A, Bost C, Ducray F, Picard G, Rogemond V, Chaffois MO, Blanc C, Bardel C, Treilleux I, Pascual O, Antoine JC, Delattre JY, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 29;2(6):e166. doi: 10.1212/NXI.0000000000000166. eCollection 2015 Dec.

29.

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.

Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, Auguste A, Pissaloux D, Boyault S, Paindavoine S, Dechelotte PJ, Besse B, Vignaud JM, Brevet M, Fadel E, Richer W, Treilleux I, Masliah-Planchon J, Devouassoux-Shisheboran M, Zalcman G, Allory Y, Bourdeaut F, Thivolet-Bejui F, Ranchere-Vince D, Girard N, Lantuejoul S, Galateau-Sallé F, Coindre JM, Leary A, Delattre O, Blay JY, Tirode F.

Nat Genet. 2015 Oct;47(10):1200-5. doi: 10.1038/ng.3399. Epub 2015 Sep 7.

PMID:
26343384
30.

[Axillary lymph node metastases with an occult breast: About 16 cases from a cohort of 7770 patients].

Couder F, Schmitt C, Treilleux I, Tredan O, Faure C, Carrabin N, Beurrier F, Chopin N.

Gynecol Obstet Fertil. 2015 Sep;43(9):588-92. doi: 10.1016/j.gyobfe.2015.06.010. Epub 2015 Aug 6. French.

PMID:
26257298
31.

TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.

Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, Chabaud S, Carrabin N, Chopin N, Bachelot T, Gillet G, Treilleux I, Rimokh R.

BMC Cancer. 2015 Jun 4;15:453. doi: 10.1186/s12885-015-1471-y.

32.

DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study.

Goulvent T, Ray-Coquard I, Borel S, Haddad V, Devouassoux-Shisheboran M, Vacher-Lavenu MC, Pujade-Laurraine E, Savina A, Maillet D, Gillet G, Treilleux I, Rimokh R.

Histopathology. 2016 Jan;68(2):279-85. doi: 10.1111/his.12747. Epub 2015 Jul 21.

PMID:
26033501
33.

Role of JMJD6 in Breast Tumourigenesis.

Poulard C, Rambaud J, Lavergne E, Jacquemetton J, Renoir JM, Trédan O, Chabaud S, Treilleux I, Corbo L, Le Romancer M.

PLoS One. 2015 May 7;10(5):e0126181. doi: 10.1371/journal.pone.0126181. eCollection 2015.

34.

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Harvey VJ, Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM.

Breast Cancer Res Treat. 2015 Jun;151(2):373-84. doi: 10.1007/s10549-015-3378-3. Epub 2015 May 3.

35.

[Postoperative morbidities after modified posterior pelvic exenteration for ovarian cancer].

Emin L, Meeus P, Beurrier F, Ferraioli D, Carrabin N, Ray-Coquard I, Treilleux I, Chopin N.

Gynecol Obstet Fertil. 2015 May;43(5):342-7. doi: 10.1016/j.gyobfe.2015.03.006. Epub 2015 Apr 18. French.

PMID:
25899113
36.

17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1.

François CM, Wargnier R, Petit F, Goulvent T, Rimokh R, Treilleux I, Ray-Coquard I, Zazzu V, Cohen-Tannoudji J, Guigon CJ.

Carcinogenesis. 2015 May;36(5):564-73. doi: 10.1093/carcin/bgv041. Epub 2015 Mar 30.

37.

[New therapeutical strategies in metastatic hormone-dependent breast cancer].

Vilquin P, Cohen P, Maudelonde T, Tredan O, Treilleux I, Bachelot T, Heudel PE.

Bull Cancer. 2015 Apr;102(4):367-80. doi: 10.1016/j.bulcan.2015.02.013. Epub 2015 Mar 21. Review. French.

38.

Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response.

Chapellier M, Bachelard-Cascales E, Schmidt X, Clément F, Treilleux I, Delay E, Jammot A, Ménétrier-Caux C, Pochon G, Besançon R, Voeltzel T, Caron de Fromentel C, Caux C, Blay JY, Iggo R, Maguer-Satta V.

Stem Cell Reports. 2015 Feb 10;4(2):239-54. doi: 10.1016/j.stemcr.2014.12.007. Epub 2015 Jan 15.

39.

[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France].

MacGrogan G, Mathieu MC, Poulet B, Penault-Llorca F, Vincent-Salomon A, Roger P, Treilleux I, Valent A, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2014 Oct;34(5):366-72. doi: 10.1016/j.annpat.2014.08.017. Epub 2014 Sep 26. French.

PMID:
25439989
40.

[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].

Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A, Mathieu MC, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Poulet B, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2014 Oct;34(5):352-65. doi: 10.1016/j.annpat.2014.08.018. Epub 2014 Sep 26. French.

PMID:
25439988
41.

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.

Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, Bourcier AV, Eymard JC, Spaeth D, Bachelot T.

Ann Oncol. 2015 Jan;26(1):120-5. doi: 10.1093/annonc/mdu497. Epub 2014 Oct 31.

PMID:
25361980
42.

Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma.

Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-101. doi: 10.1097/IGC.0000000000000263. Review.

PMID:
25341589
43.

Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix.

Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, Pautier P, Reed NS, Fujiwara K.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S102-8. doi: 10.1097/IGC.0000000000000262. Review.

PMID:
25341572
44.

A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.

Nguyen NT, Vendrell JA, Poulard C, Győrffy B, Goddard-Léon S, Bièche I, Corbo L, Le Romancer M, Bachelot T, Treilleux I, Cohen PA.

Mol Oncol. 2014 Dec;8(8):1441-57. doi: 10.1016/j.molonc.2014.05.013. Epub 2014 Jun 10.

45.

Management of patients diagnosed with atypical ductal hyperplasia by vacuum-assisted core biopsy: a prospective assessment of the guidelines used at our institution.

Caplain A, Drouet Y, Peyron M, Peix M, Faure C, Chassagne-Clément C, Beurrier F, Fondrevelle ME, Guérin N, Lasset C, Treilleux I.

Am J Surg. 2014 Aug;208(2):260-7. doi: 10.1016/j.amjsurg.2013.10.029. Epub 2014 Jan 23.

PMID:
24680949
46.

The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.

Cassier PA, Floquet A, Penel N, Derbel O, Bui N'guyen B, Guastalla JP, Pissaloux D, Treilleux I, Saba CE, Blay JY, Ray-Coquard I.

Ann Oncol. 2014 May;25(5):1074-5. doi: 10.1093/annonc/mdu045. Epub 2014 Mar 20. No abstract available.

PMID:
24651409
47.

LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer.

Bouchekioua-Bouzaghou K, Poulard C, Rambaud J, Lavergne E, Hussein N, Billaud M, Bachelot T, Chabaud S, Mader S, Dayan G, Treilleux I, Corbo L, Le Romancer M.

Int J Cancer. 2014 Sep 15;135(6):1307-18. doi: 10.1002/ijc.28781. Epub 2014 Mar 4.

48.

[Spontaneous regression of breast cancer after biopsy. About two cases].

Maillet L, Chopin N, Treilleux I, Bachelot T, Tredan O, Faure C, Caux C, Beurrier F.

Gynecol Obstet Fertil. 2014 Apr;42(4):269-72. doi: 10.1016/j.gyobfe.2013.08.017. Epub 2014 Jan 3. French.

PMID:
24394327
49.

Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death.

Paradisi A, Creveaux M, Gibert B, Devailly G, Redoulez E, Neves D, Cleyssac E, Treilleux I, Klein C, Niederfellner G, Cassier PA, Bernet A, Mehlen P.

EMBO Mol Med. 2013 Dec;5(12):1821-34. doi: 10.1002/emmm.201302654. Epub 2013 Oct 8.

50.

Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network.

Maillet D, Goulvent T, Rimokh R, Vacher-Lavenu MC, Pautier P, Alexandre J, Pujade-Laurraine E, Devouassoux-Shisheboran M, Treilleux I, Ray-Coquard I, Savina A.

Gynecol Oncol. 2014 Jan;132(1):181-7. doi: 10.1016/j.ygyno.2013.10.013. Epub 2013 Oct 22.

PMID:
24157616

Supplemental Content

Loading ...
Support Center